{"id":"h5n1-vaccine-arepanrix","safety":{"commonSideEffects":[{"rate":"30–50","effect":"Injection site pain or erythema"},{"rate":"20–40","effect":"Myalgia"},{"rate":"15–30","effect":"Headache"},{"rate":"10–25","effect":"Fatigue"},{"rate":"5–15","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated H5N1 virus particles that have been chemically split to reduce reactogenicity while preserving immunogenicity. It is formulated with an oil-in-water emulsion adjuvant (AS04) that enhances the immune response by activating both innate and adaptive immunity, promoting stronger and more durable antibody production against H5N1 surface antigens.","oneSentence":"Arepanrix is an inactivated split-virion H5N1 influenza vaccine that stimulates the immune system to produce antibodies against the H5N1 avian influenza virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:22:43.380Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of H5N1 influenza infection in at-risk populations"}]},"trialDetails":[{"nctId":"NCT07275060","phase":"PHASE4","title":"Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-10-14","conditions":"H5N1 Influenza, H5N1 Virus, Avian Influenza","enrollment":312},{"nctId":"NCT07240558","phase":"PHASE3","title":"Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-11-03","conditions":"Influenza (Pandemic), Avian Influenza, Vaccination","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Arepanrix","GSK"],"phase":"marketed","status":"active","brandName":"H5N1 vaccine (Arepanrix)","genericName":"H5N1 vaccine (Arepanrix)","companyName":"Canadian Immunization Research Network","companyId":"canadian-immunization-research-network","modality":"Biologic","firstApprovalDate":"","aiSummary":"Arepanrix is an inactivated split-virion H5N1 influenza vaccine that stimulates the immune system to produce antibodies against the H5N1 avian influenza virus. Used for Prophylaxis of H5N1 influenza infection in at-risk populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}